Cargando…

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies. However, CAR-T cells also cause the release of pro-inflammatory cytokines that lead to life-threatening cytokine release syndr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreros, Puri, Trapero, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326641/ https://www.ncbi.nlm.nih.gov/pubmed/35892735 http://dx.doi.org/10.3390/diseases10030041

Ejemplares similares

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
por: Xiao, Xinyi, et al.
Publicado: (2021)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
por: Morris, Emma C., et al.
Publicado: (2021)

Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy
por: Balagopal, Srinivas, et al.
Publicado: (2022)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell
por: Catino, Anna B.
Publicado: (2020)

Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
por: Thakar, Monica S., et al.
Publicado: (2020)

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
por: Siegler, Elizabeth L., et al.
Publicado: (2020)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

T-cell Therapy-Mediated Myocarditis Secondary to Cytokine Release Syndrome
por: Afzal, Anoshia, et al.
Publicado: (2020)

Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy
por: Moriyama, Shohei, et al.
Publicado: (2022)

Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
por: Gu, Tianning, et al.
Publicado: (2022)

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)
por: Chen, Jia-Jie, et al.
Publicado: (2021)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy
por: Yoshihara, Kyoko, et al.
Publicado: (2022)

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
por: Liu, Yanfen, et al.
Publicado: (2018)

Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy
por: Liu, Haiyan, et al.
Publicado: (2019)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy
por: Boulch, Morgane, et al.
Publicado: (2023)

Cytokine release syndrome: grading, modeling, and new therapy
por: Liu, Delong, et al.
Publicado: (2018)

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
por: Möhn, Nora, et al.
Publicado: (2022)

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
por: Belin, Catherine, et al.
Publicado: (2020)

The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy
por: Adkins, Sherry
Publicado: (2019)

The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy
Publicado: (2019)

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
por: Wei, Jianshu, et al.
Publicado: (2020)

Cytokine Release Syndrome: Current Perspectives
por: Murthy, Hemant, et al.
Publicado: (2019)

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Isorhamnetin Attenuated the Release of Interleukin-6 from β-Amyloid-Activated Microglia and Mitigated Interleukin-6-Mediated Neurotoxicity
por: Wei, Pei-Cih, et al.
Publicado: (2022)

Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
por: Du, Peng, et al.
Publicado: (2021)

Novel pathophysiological insights into CAR-T cell associated neurotoxicity
por: Genoud, Vassilis, et al.
Publicado: (2023)

Editorial: Novel insights into CAR T-cell associated neurotoxicity
por: Bouziana, Stella
Publicado: (2023)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u7bvj84s9s1uf11f01csvvn6fo